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understood. In this study, we demonstrate that Mo-MDSC 
(CD11b+/gr1+/ly6g−/ly6Chi) significantly increase the 
frequency of alDH1Bright CSCs in a mouse model of PC. 
additionally, there was significant upregulation of genes 
associated with epithelial to mesenchymal transition. We 
also found that human PC converts CD14+ peripheral 
blood monocytes into Mo-MDSC (CD14+/Hla-Drlow/−) 
in vitro, and this transformation is dependent on the acti-
vation of the Stat3 pathway. In turn, these Mo-MDSC 
increase the frequency of alDH1Bright CSCs and promote 
mesenchymal features of tumor cells. Finally, blockade 
of Stat3 activation reversed the increase in alDH1Bright 
CSCs. these data suggest that the PC tumor microenvi-
ronment transforms monocytes to Mo-MDSC by Stat3 
activation, and these cells increase the frequency of alD-
H1Bright CSCs. therefore, targeting Stat3 activation may 
be an effective therapeutic strategy in targeting CSCs in 
PC.
Keywords Monocytic MDSC · Stem cell · epithelial 
to mesenchymal transition · Pancreatic cancer · Stat3 
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Abbreviations
CCr2  Chemokine (C–C motif) receptor 2
CSC  Cancer stem cell
g-CSF  granulocyte colony-stimulating factor 
(CSF-3)
g-MDSC  granulocytic myeloid-derived suppressor 
cell
Mo-MDSC  Monocytic myeloid-derived suppressor cell
PC  Pancreatic cancer
Stat3  Signal transducer and activator of transcrip-
tion 3
taM  tumor-associated macrophage
Abstract Pancreatic cancer (PC) mobilizes myeloid 
cells from the bone marrow to the tumor where they 
promote tumor growth and proliferation. Cancer stem 
cells (CSCs) are a population of tumor cells that are 
responsible for tumor initiation. aldehyde dehydro-
genase-1 activity in PC identifies CSCs, and its activ-
ity has been correlated with poor overall prognosis in 
human PC. Myeloid cells have been shown to impact 
tumor stemness, but the impact of immunosuppressive 
tumor-infiltrating granulocytic and monocytic myeloid-
derived suppressor cells (Mo-MDSC) on alDH1Bright 
CSCs and epithelial to mesenchymal transition is not well 
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Introduction
Pancreatic cancer (PC) is a highly aggressive malignancy 
which is characterized by early metastasis and chemothera-
peutic resistance [1]. PC has a uniquely dense stroma with 
abundant leukocytes, which are predominantly myeloid 
cells. these myeloid cells are heterogeneous; primarily 
comprised of macrophages and monocytic and granulo-
cytic myeloid-derived suppressor cells (Mo- and g-MDSC, 
respectively) [2]. these cells are produced in the bone mar-
row, are actively recruited to the tumor microenvironment 
by tumor-derived chemokines, and promote tumor growth 
and spread through various mechanisms [3–5].
their clinical importance is demonstrated by the finding 
that in a number of cancer types including PC, increased 
prevalence of myeloid cells in the tumor microenviron-
ment is an independent prognostic factor for survival [6]. 
tumor-associated myeloid cells have been shown to corre-
late with disease stage, resectability, and survival in PC [7, 
8]. typical of tumor-infiltrating myeloid cells is their abil-
ity to suppress antitumor immunity [9]. In addition, they 
can also directly promote tumor cell proliferation, invasion 
and thus facilitate metastasis, and therapeutic resistance 
[7, 10].
Cancer stem cells (CSCs) are an important subpopu-
lation of tumor cells which are capable of tumor initia-
tion and are resistant to chemotherapy [11]. In PC, CSCs 
were first identified as CD24+/CD44+/eSa+ cells [12]. 
aldehyde dehydrogenase-1 (alDH1) is a relatively new 
marker which is an intracellular detoxifying enzyme origi-
nally identified as a phenotypic marker for hematopoietic 
stem cells [13, 14]. We and others have previously demon-
strated that alDH1 is also an important marker of CSCs in 
PC [15, 16]. In fact, patients having tumors with increased 
alDH1Bright CSCs have decreased progression free and 
overall survival [16]. It is not entirely clear how levels of 
alDH1Bright CSCs are regulated, but there is mounting 
evidence for a dynamic interplay between the stroma and 
tumor cells which promotes epithelial to mesenchymal 
transition (eMt) and tumor stemness [17, 18].
the role of mature tumor-associated macrophages 
(taMs) in promoting stemness in a murine model of 
PC has been demonstrated by Mitchem et al. However, 
the role of Mo-MDSC in PC is not well understood. In 
this study, g-MDSC and Mo-MDSC from both mice 
(g-MDSC: CD11b+/gr1+/ly6g+/ly6Cmid, Mo-MDSC: 
CD11b+/gr1+/ly6g−/ly6Chi) and humans (g-MDSC: 
lin−/CD11b+/CD33+/CD15+, Mo-MDSC: lin−/CD11b+/
CD33+/CD14+/Hla-Drlow/−) [19, 20] were assessed for 
their impact on alDH1Bright CSC in mouse and human 
PC. We demonstrate that Mo-MDSC-infiltrating PC tumors 
promote the alDH1Bright CSC population by activation 
of Stat3. We also show that cancer stem cell promoting 
activity can be blocked by inhibition of the Stat3 signal-
ing pathway.
Materials and methods
Bone marrow samples from pancreatic cancer patients 
and healthy controls and collection of PC tissue 
from patients
Blood, bone marrow samples (N = 16), and tumor sam-
ples (N = 11) were collected from patients with resectable 
PC at Barnes-Jewish Hospital (St. louis, MO, USa). these 
patients received no chemotherapy or radiation therapy prior 
to surgery. Informed consent was obtained on all patients in 
accordance with Institutional review Board (IrB)-approved 
protocol. normal bone marrow was obtained from age-
matched healthy cancer free volunteers (N = 7). Bone mar-
row samples were collected in vacuum tubes containing lith-
ium heparin (BD Vacutainer), and mononuclear cells were 
isolated by Ficoll density centrifugation. normal pancreas 
tissue was collected from patients (N = 4) who were eligi-
ble for organ donation and had no malignant disease. Par-
affin slides of normal human pancreas tissue (N = 5) were 
obtained from abcam, genetex, IHC world, and Imgenex.
Pancreatic cancer tissue microarray survival analysis
after obtaining IrB approval, tissue microarray (tMa) 
studies were conducted on a cohort of 60 previously 
untreated patients with pancreatic ductal adenocarcinoma 
who underwent pancreaticoduodenectomy at Barnes-Jewish 
Hospital. Patients did not receive neo-adjuvant therapy and 
were typically treated with adjuvant chemotherapy. to con-
struct the tMa, well-defined areas of tumor were demar-
cated and punched (1 mm diameter) from paraffin-embed-
ded tumor blocks. an aperio Scan-Scope Xt Slide Scanner 
(aperio technologies) system was used to acquire digital 
images using a 20× objective. a tumor-specific nuclear 
algorithm (IHC-MarK) developed in-house [15] was mod-
ified to quantify CD14, CD8, and alDH1 expression.
Stat3 inhibitor
StattIC (Stat3 inhibitor V) was obtained from 
Calbiochem/eMD and used at doses less than the reported 
IC50 (<20 µM) in vitro according to manufacturer instruc-
tions [21].
Cell lines
KCM and KCKO were a kind gift from Dr. Mukherjee 
[22], Panc-1 and BxPC3 were purchased from atCC, and 
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Pan02 [23], from the Division of Cancer treatment tumor 
repository (nCI-Frederick Cancer research and Develop-
ment Center, Bethesda, MD).
animal husbandry
gCSFr−/− mice were a kind gift from Daniel C. link 
(Internal Medicine/Division of Oncology). C57Bl/6 and 
nU/J mice were purchased from Jackson laboratories. 
Mice were maintained within the Washington University 
laboratory for animal Care barrier facility and all studies 
involving animals were approved by the Washington Uni-
versity School of Medicine Institutional animal Studies 
Committee.
Orthotopic model and preclinical animal cohorts
Six- to eight-week-old gCSFr−/− and wild-type (Wt) 
mice were injected in the tail of the pancreas with 1 × 105 
murine tumor cells suspended in 50 μl of PBS and Matrigel 
(mixed 1:1). Mice were sacrificed at 31 days post-injection 
and peripheral blood, bone marrow, and tumors were col-
lected. the bone marrow was extracted from femurs via 
high-speed centrifugation, and blood samples were col-
lected in heparinized capillary tubes from retro-orbital 
sinus. Blood and bone marrow were washed once with 
sterile phosphate buffered saline (PBS) and subjected to 
red blood cell (rBC) lysis, according to manufacturer’s 
instructions (rBC lysis buffer, Biolegend). We measured 
gross wet weight of orthotopic tumors. the tumors were 
minced into 2–3-mm-size pieces, mechanically dissoci-
ated using the Miltenyi gentle-MaCS tissue dissociator 
and digested in enzyme buffer that contained 1 mg/ml col-
lagenase, 2.5 U/ml hyaluronidase and 0.1 mg/ml of Dnase 
for 30 min at 37 °C. Digestion mixtures were quenched by 
adding DMeM with 10 % FBS and filtered through 70-μm 
nylon strainers (BD falcon) and were counted. Pieces of 
tumor were also snap frozen in liquid nitrogen. Mice were 
injected with 2 × 105 tumor cells in 100 μl PBS subcuta-
neously, and tumor volume was calculated at specific time 
intervals by caliper measurements. We used 7–10 mice per 
group, and all these experiments were repeated in triplicate. 
all experiments were carried out according to animal stud-
ies committee guidelines.
Flow cytometry
Human and mouse single cell suspensions were blocked 
with truStain FcX or anti CD16/32 antibody, respectively 
(Biolegend) and stained with fluorescent antibodies using 
standard protocols for flow cytometry. to stain alDH-
Bright
 cells, the aldefluor assay was performed according 
to the manufacturer’s protocol (Stem Cell technologies). 
For intracellular staining of cells, we used permeabiliza-
tion buffer (eBioscience). We used CD45 (aF700; Biole-
gend, HI30), CD11b (aF488 and Pacific Blue; Bioleg-
end, ICrF44), CD115 (Pe; Biolegend, 9-4D21e4), CD14 
(aPC/Cy7; Biolegend, M5e2), CD15 (Pacific Blue; Biole-
gend, W6D3), CD68 (aPC; Biolegend, CD68), Hla-Dr 
(Pe/Cy7; BIolegend, l243), CD4 (PerCP/Cy5.5; eBio-
science, rPa-t4), CD8 (Pacific Blue; Biolegend, SK1), 
epCaM (Pac Blue; Biolegend, 9C4), CD24(Pe/Cy7; Bio-
legend, Ml5), CD44 (aPC/Cy7; Biolegend, IM7), and PPI 
(Biolegend) for human tumors. For mice, we used CD45 
(aPC/Cy7; Biolegend, 30-F11), CD11b (aPC; Bioleg-
end, M1/70), ly6C (Pe/Cy7; Biolegend HK1.4), ly6g 
(Pacific Blue; Biolegend, 1a8), gr-1 (aF700; Biolegend, 
rB6-865), F4/80 (PerCpCy5.5; Biolegend, BM8), I-a/I-
e (aF488; Biolegend, M5/114.15.2), CD4 (aF700; Bio-
legend, gK1.5), CD8a (Pe; Biolegend, 53-6.7), epCaM 
(Pe/Cy7; Biolegend, g8.8), CD24 (PerCP/Cy5.5; Biole-
gend, M1/69), CD44 (aPC/Cy7; Biolegend, IM7), and 
PPI(Biolegend). Data acquisition and analysis were per-
formed using an lSrII system (BD Biosciences), aria II 
High Speed Cell Sorter (BD Biosciences) for fluorescence-
activated cell sorting (FaCS) and FlowJo version 7.6.5 
software (tree Star).
rna isolation and rt-PCr
Snap-frozen tissue from mouse and human was homog-
enized in trIzol reagent (life technologies), and total 
rna was isolated according to the manufacturer’s guide-
lines. rna samples were treated with Dnase (Promega), 
and the rna was extracted with the rneasy Mini Kit using 
the manufacturer’s instructions for rna clean up (Qiagen). 
rna was reverse transcribed into cDna using the high 
capacity rna-to-cDna kit (life technologies), and real-
time PCr reactions were prepared by mixing cDna with 
taqman FaSt universal PCr Master Mix and pre-designed 
taqman gene expression assays (life technologies). real-
time PCr was performed on a 7500 FaSt thermal cycler 
(applied Biosystems). target gene expression was normal-
ized to gaPDH, HPrt, or β-actin. target gene expression 
was determined using the comparative Ct (ΔΔCt) method 
with 7500 software for 7500 rt-PCr system version 2.0.6 
(applied Biosystems).
CD8 suppression assays
PBMCs were isolated from healthy volunteers by Ficoll 
density centrifugation. CD14+ cells were isolated from the 
PBMCs of healthy volunteers with the easySep® Human 
CD14 Positive Selection Kit according to the manufac-
turer’s instructions (Stemcell technologies™). CD14+ 
cells were cocultured with BXPC3 or Panc-1 tumor cells 
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in a transwell plate to prevent cell to cell contact between 
the two populations. the CD14+ cells were mixed 1:1 
with autologous PBMCs labeled with 10 μM CFSe (life 
technologies) in 96-well round-bottom plates (Corning) 
coated with 1 μg/ml leaF™ purified anti-human CD3 
(Biolegend, clone OKt3) in complete media [rPMI con-
taining 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml 
streptomycin, 1 mM sodium pyruvate (life technologies), 
and 10 % fetal bovine calf serum (Hyclone)] supplemented 
with 100 U/ml of human interleukin 2 (national Institute of 
Health). Cell cultures were harvested after 72 h at 37 °C, 
and the CFSe dilution of the CD4+ and CD8+ t cell frac-
tions was analyzed by flow cytometry.
In order to test the immunosuppressive properties of 
mouse Mo-MDSC, total mouse bone marrow was isolated 
from the femur and tibia of Wt and g-CSFr−/− mice by 
high-speed centrifugation. Bone marrow was subjected to 
rBC lysis in tris lysing buffer (144 mM nH4Cl, 17 mM 
tris–HCl, pH 7.2), and CD11b+ cells were isolated using 
the mouse CD11b positive selection kit according to the 
manufacturer’s instructions (Stemcell technologies). 
CD11b+ cells were converted into Mo-MDSC by incu-
bating in Pan02-conditioned medium for 72 h at 37 °C in 
6-well flat-bottom plates. tumor-conditioned media was 
prepared by incubating Pan02 in complete media in t75 
flasks for 72 h at 37 °C followed by 0.2 μm filtration. Sin-
gle cell suspensions of mouse splenocytes were prepared 
by crushing the spleens of Wt mice in PBS and filtering 
the suspensions over 40 μm filters. Single cell suspensions 
were subjected to rBC lysis and splenocytes were labeled 
with CFSe as described above. labeled splenocytes were 
cocultured in complete media supplemented with 50 μM 
2-mercaptoethanol in 96-well round-bottom plates (Corn-
ing) coated with 0.5 μg/ml leaF™ purified anti-mouse 
CD3 (Biolegend, clone 145-2C11) and varying concentra-
tions of CD11b+ cells previously treated with complete 
media alone or tumor-conditioned media. In some wells, 
arginase-1 activity was inhibited by adding nor-nOHa 
(Calbiochem) at a final concentration of 0.5 mM. Cell cul-
tures were harvested after 72 h at 37 °C, and the CFSe 
dilution of the CD4+ and CD8+ t cell fractions was ana-
lyzed by flow cytometry.
Immunofluorescence
Formalin-fixed paraffin-embedded tissue blocks of archived 
human pancreatic ductal adenocarcinoma were cut at 5 μm 
using a leica rM2235 microtome. Cut tissue sections 
were then floated onto SuperFrost Plus slides (Fisher Sci-
entific) in a 42 °C water bath and dried overnight. normal 
pancreas tissue previously cut and mounted on glass slides 
was purchased from Imgenex. tissue sections were heated 
for 30 min at 65 °C and deparaffinized in three changes of 
xylene. the sections were then rehydrated in serial changes 
in decreasing ethanol in deionized water (100, 95, 70, 
50 %, then deionized H2O) and rinsed in PBS. tissue sec-
tions were submerged in citrate buffer (10 mM sodium cit-
rate, 0.05 % tween 20, pH 6) or target retrieval Solution 
(DaKO, pH 9), and antigen retrieval was performed in a 
decloaking chamber (Biocare Medical). the sections were 
washed in running deionized water and rinsed in PBS. tis-
sue sections were then blocked for 30 min at room tempera-
ture in Serum-Free Protein Block (DaKO) and stained with 
primary antibodies diluted in antibody Diluent (DaKO) 
overnight at 4 °C. the following primary antibodies were 
used in this study: mouse anti-alDH1, clone 44/alDH 
(BD, 1:100); rabbit anti-CD11b, clone M1/70 (abcam, 
1:100); mouse anti-CD14 (thermo Fisher Scientific Inc., 
1:20); mouse anti-CD15, clone MY-1 (abcam, 1:10); 
mouse anti-keratin 7, clone OV-tl 12/30 (thermo Fisher 
Scientific, 1:50); and mouse anti-phospho-Stat3, clone 
D3a7 (Cell Signaling technology, 1:400). tissue sections 
were washed in PBS then stained with alexa 488 goat anti-
mouse Igg and alexa 555 goat anti-rabbit Igg secondary 
antibodies (life technologies) diluted 1:200 in antibody 
Diluent for 30 min at room temperature. tO-PrO-3 iodide 
(life technologies) was added to the secondary antibody 
cocktail at a final concentration of 1 μM to visualize cel-
lular nuclei. the tissue sections were washed in PBS, and 
then, the excess PBS was blotted off and sections were 
coverslipped with Vectashield Hard Mounting Media (Vec-
tor labs). Confocal images were acquired on an axiovert 
100M microscope equipped with a lSM 510 Meta Con-
focal laser Scanning Microscope system (Zeiss).
Western blotting
CD14+ cells previously cocultured with Panc-1 tumor 
cells (separated by a transwell insert) or cultured in com-
plete media alone. after coculture, CD14+ cells were sepa-
rated and washed with 1× PBS and lysed in rIPa buffer 
containing a protease inhibitor (roche) and phosphatase 
inhibitor (Sigma) cocktails. Cell lysates were sonicated for 
10 s then centrifuged at 4 °C for 10 min at 14,000×g. the 
supernatant was removed and protein concentration was 
determined using a BCa Protein assay kit (lamda Biotech, 
Inc.,). twenty microgram of total protein was prepared for 
denaturing gel electrophoresis under non-reducing condi-
tions in nuPage® lDS buffer according to the manufac-
turer’s instructions and loaded onto nuPage® 4–12 % Bis–
tris gels in an XCell Surelock Mini-Cell containing 1× 
nuPage® MOPS SDS running buffer (life technologies). 
gels were run at 200 V for 50 min and then blotted onto 
PVDF membranes in an XCell Surelock Mini-Cell by wet 
transfer with 1× nuPage transfer buffer (life technolo-
gies). after transfer, the blots were rinsed in washing buffer 
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(tBSt: 20 mM tris base, 137 mM naCl, 0.1 % tween 
20, pH 7.6) and blocked in blocking buffer (5 % non-fat 
dry milk in tBSt) for 1 h at room temperature. the mem-
branes were washed in tBSt and incubated in rabbit anti-
phospho-Stat3 (Cell Signaling technologies, clone D3a7; 
1:2,000) or goat anti-actin (Santa Cruz Biotechnology, Inc., 
1:200) primary antibodies diluted in tBSt with 5 % BSa 
overnight at 4 °C. Membranes were washed in tBSt and 
incubated in goat anti-rabbit Igg-HrP (Santa Cruz Bio-
technology, Inc., 1:2,000) or donkey anti-goat Igg-HrP 
(Santa Cruz Biotechnology, Inc., 1:5,000) diluted in block-
ing buffer for 1 h at room temperature. the membranes 
were washed in tBSt and protein bands were visualized 
with SuperSignal West Dura extended Duration Substrate 
(thermo Fisher Scientific). Blot images were acquired with 
a ChemiDoc XrS+ imaging system (Bio-rad).
Invasion assays
BD BioCoat Matrigel Invasion chambers (Catalog# 
354480) were used to study the invasion of tumor cell 
lines cocultured with and without CD11b+ or CD14+ cells. 
BD BioCoat chambers (24-well) were rehydrated using 
bicarbonate-based culture medium. CD11b+ and CD14+ 
cells were isolated from mice and humans, respectively, as 
described above and were plated in the bottom of 6-well 
chambers. the transwell inserts were placed in the cham-
ber after 6 h of plating cells. Single cell suspensions of 
tumors (BxPC3, Panc-1, KCKO, KCM) were made in cul-
ture medium, and 2.5 × 104 tumor cells (in 0.5 ml of cul-
ture medium) were added on top of the transwell insert to 
assess their ability to migrate/invade (downward) through 
the Matrigel-coated membrane. the cells were incubated in 
a humidified tissue culture incubator at 37 °C for 22 h. the 
non-invading cells were removed from the upper surface of 
the membrane using a Q-tip. the cells that invaded through 
the Matrigel-coated membrane were then fixed using 100 % 
methanol. after fixation, the cells that invaded through 
Matrigel membrane were stained using 1 % toluidine blue 
(Sigma, Catalog# 198161). the inserts were washed with 
diH2O, air-dried, and membranes were removed from the 
inserts. the membranes were placed on a microscope slide 
with a small drop of immersion oil, and a cover slip was 
placed on top. Images of invaded cells were acquired under 
microscope at 40× magnification using SPOt rt digital 
camera and software. Cells were counted in six different 
fields of triplicate membranes.
Human and mouse bone marrow colony-forming unit 
(CFU) assay
Methylcellulose-based culture (MC) media (MethoC-
ult, StemCell technologies Catalog# 03001) was thawed 
under refrigeration (2–8 °C) overnight. Bone marrow 
cells were isolated from both human and mouse and were 
resuspended in PBS with 2 % FBS at 2 × 106 cells/ml. 
the cell suspension was added to Methocult medium at 
a 1:10 ratio to maintain correct medium viscosity. three 
milliliter of the suspension was drawn and plated in a 
35 mm low-adherence petri dish with a loose fitting lid. 
the petri dishes were placed in a large petri dish and 
incubated in a humidified tissue culture incubator at 37 °C 
for 7 days. granulocyte and macrophage colony-form-
ing units (CFU-gM) were counted at 25× to 50× and a 
higher magnification was used to confirm CFU type. the 
comparison was made between PC patient bone marrow 
and healthy donor bone marrow. For mouse studies, the 
comparison was made between gCSFr−/− and Wt bone 
marrow.
Coculture experiments with transwell insert
all cocultures were performed using transwell inserts (BD 
Falcon Catalog# 353090) so the tumor cells were separated 
from myeloid cells. CD14+ cells or CD11b+ cells sus-
pended in cell culture medium were plated on the 6-well 
cell culture plate (costar# 3516). the transwell inserts 
were gently transferred into the previously filled wells 
(with CD11b+ or CD 14+ cells), and tumor cell suspen-
sion was added on top of the transwell insert. tumor cells 
were isolated after coculture by removing the transwell 
inserts. CD14+ cells from the bottom were separately har-
vested. Isolated tumor cells and CD14+ cells were washed, 
and flow cytometry rt-PCr, and Western blotting were 
performed.
Statistical analysis
graphpad prism V (graphpad Software Inc.,) was used for 
statistical analysis. For nonparametric data Mann–Whit-
ney test and for parametric data unpaired t test was used 
p < 0.05 was considered statistically significant.
Results
Pancreatic cancer is characterized by abundant 
granulocytic and monocytic myeloid cells as well 
as alDH1Bright cancer stem cells
PC tumors possess a dense stroma characterized by abun-
dant immunosuppressive myeloid cells [24]. However, 
myeloid cells are heterogeneous with different pheno-
types. therefore, we sought to better characterize these 
cells in human PC and found that both CD14+ (mono-
cytic) and CD15+ (granulocytic) myeloid cells were 
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highly prevalent by both flow cytometry analysis and 
immunofluorescence confocal microscopy (Fig. 1a, b). a 
significant population of CD14+ cells within the tumor 
had low Hla-Dr expression by flow cytometry, a char-
acteristic of Mo-MDSC (Fig. 1a). Unlike PC, however, 
normal human pancreas has significantly fewer number 
of CD45+ cells (including CD14+, CD15+ myeloid infil-
trate) compared with human PC (Fig. 1a, c; Supplemen-
tary figures 1, 2).
We hypothesized that the high prevalence of MDSC 
in the tumor microenvironment was a result of enhanced 
myelopoiesis in the bone marrow of PC patients and active 
recruitment to the tumor. In order to study the effect of 
tumors on bone marrow myelopoiesis, we measured the 
myeloid progenitor cells by performing granulocyte mac-
rophage colony-forming unit assays (CFU-gM) using 
bone marrow aspirates of PC patients and healthy controls. 
Indeed, bone marrow from PC patients formed significantly 
more CFU-gM compared to age-matched healthy controls 
(Fig. 1d). this suggests that tumors enhance myelopoiesis 
in the bone marrow of PC patients.
as previously stated, alDH1 defines a subpopulation 
of treatment-resistant cancer cells with enhanced tumor-
initiating properties in PC [14, 16]. Our group previ-
ously reported that alDH1Bright murine PC cells express 
higher levels of CD29, CD44, and CD49f, and we func-
tionally characterized this population of cells by both in 
vitro spheroid assays and in vivo tumorigenic potential 
in nude mice. We also demonstrated that enrichment of 
alDH1Bright cells promotes chemoresistance in PC [15]. 
Here, we performed flow cytometry and immunofluores-
cence staining and found that alDH1Bright CSCs [iden-
tified as CD45−, epCaM+ and propidium iodide (PI)−] 
composed roughly 6–10 % of tumor cells (Fig. 1e) 
compared to normal human pancreas (Supplementary 
figure 3).
to understand the clinical implications of the CD14+ cell 
infiltrate, we analyzed a tissue tMa from 60 PC patients. 
tumors were scored for the presence of CD14+ and leu-
kocytes and stratified into four groups (CD14Hi/CD8low, 
CD14low/CD8low, CD14Hi/CD8Hi, and CD14low/CD8Hi). 
We observed that patients with predominant CD14+/
CD8low infiltrate in the tumor had a significantly reduced 
overall survival compared to all other groups (denoted as 
CD14low/CD8low, CD14Hi/CD8Hi, and CD14low/CD8Hi, 
p value <0.001) (Fig. 1f). Further analysis showed that 
CD14+ leukocytes correlated with tumor alDH1 expres-
sion (Spearman’s r = 0.2, p = 0.02) and tumors classified 
as CD14Hi had increased alDH1Bright cells (Supplementary 
figure 4). this led us to examine the link between the abun-
dant MDSC infiltrate and the alDH1Bright CSC sub popu-
lation, which is a well-established cancer stem cell popula-
tion in murine PC model [15].
gCSFr−/− mice with pancreatic cancer exhibit impaired 
myelopoiesis
to further study the potential relationship between tumor-
induced bone marrow myelopoiesis and increased alD-
H1Bright CSCs in tumors, we employed a mouse model. 
granulocyte colony-stimulating factor (g-CSF/CSF-3) is 
a critical growth factor for myeloid cell production in the 
bone marrow [25, 26]. We utilized a g-CSF receptor knock 
out (gCSFr−/−) mouse model (on a C57Bl/6 genetic back-
ground) to study the effects of myelopoiesis in PC. these 
mice are unique in that they cannot increase myelopoiesis 
in response to physiologic triggers, including tumors [25, 
27]. We utilized three distinct murine PC cell lines, denoted 
as KCM, KCKO, and Pan02, derived from spontaneous 
PC arising from genetic models (lSl-KraSg12D × P48-
Cre × MUC1 and lSl-KraSg12D × p48-Cre, respec-
tively) or tumors arising from 3-methylcholanthrene 
carcinogenesis (Pan02) [23]. We implanted tumor cells 
subcutaneously in Wt and gCSFr−/− mice and isolated 
bone marrow from both tumor bearing and non tumor bear-
ing mice. tumor bearing gCSFr−/− mice had significantly 
less CFU-gM as compared to Wt mice ex vivo (Fig. 2a). 
Similar to PC patients, we observed an increase in bone 
marrow myelopoiesis and MDSC (CD11b+, gr1+) in the 
peripheral blood of tumor-bearing Wt mice [7]. In vivo, 
gCSFr−/− mice were not able to upregulate myelopoiesis 
in response to PC implantation, which translated into sig-
nificantly reduced g-MDSC and Mo-MDSC in the blood 
of tumor-bearing mice (Fig. 2b). However, MDSC from 
tumor-bearing Wt and gCSFr−/− mice were similarly 
immunosuppressive ex vivo (Supplementary figure 5). We 
have studied the direct ligand-receptor expression and iden-
tified that tumor cells do not express gCSF receptor (data 
not shown). this suggests that while gCSFr−/− mice have 
reduced myelopoiesis, their myeloid cells retain immu-
nosuppressive properties, thus meeting the definition of 
MDSC [28].
MDSC reduction alters the tumor microenvironment 
and correlates with decreased frequency of alDH1Bright 
CSCs in murine pancreatic cancer
Because PC is characterized by an abundant stroma where 
myeloid cells predominate, we sought to determine the rela-
tionship between MDSC and alDH1Bright CSCs using the 
gCSFr−/− mouse model. gCSFr−/− mice have significantly 
decreased tumor-infiltrating g-MDSC and Mo-MDSC, com-
pared to Wt tumors. In addition, there was a corresponding 
increase in tumor-infiltrating CD8+ t cell infiltrate while 
CD4+ t cells and macrophages (defined as CD45+/CD11b+/
F4/80hi/ly6Clow/MHCII+) were unchanged (Fig. 2c). the 
bar graph shows infiltrating tumor cells as a percentage of 
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Fig. 1  Myeloid cells and alDH1Bright cells are prevalent in PC. a Flow 
cytometry performed on human PC samples (N = 11) and normal human 
pancreas (N = 4). representative flow cytometry plot of normal human 
pancreas and PC tumor compares CD45+ infiltrate. Flow cytometry 
plots gating on CD45+ cells shows CD14+ and CD15+ infiltrate in the 
tumor. a significant population of CD14+ cells is Hla-Drlow/−. a rep-
resentative flow plot shows 2.68 % CD45+ cells infiltrating the normal 
human pancreas (gating is performed using isotype control). b Immuno-
fluorescent staining was performed on normal human pancreas samples 
(N = 5) and PC samples (N = 5). representative immunofluorescent 
confocal images (×63) of normal human pancreas and PC stained for 
(CD11b, CD14), (CD11b, CD15). Green CD14 or CD15, red CD11b 
and blue Topro. c a histogram reporting percentages (average values) 
of the monocytic and granulocytic myeloid cells and t cells infiltrating 
the tumor as a percentage of total cells in PC tissue (N = 11) compared 
to normal human pancreas (N = 4). granulocytes (normal pancreas 
(mean ± SD) = 1.87 ± 0.5 and PC = 14.6 ± 0.65, p value <0.05) and 
monocytes (normal = 1.3 ± 0.7 and PC = 12.4 ± 1.07, p value <0.05) 
are significantly increased in PC. d Upregulation of myelopoiesis in 
human PC; bone marrow specimens were collected from PC patients 
(N = 16) and age-matched healthy controls (N = 7); methylcellulose-
based colony-forming unit assays were performed as described in “Mate-
rials and methods” section and were scored for the total number of mye-
loid colonies (CFU-gM) after 8 days. Bar graph depicts mean ± SeM 
and asterisk denotes statistically significant difference between the two 
groups p < 0.05 by Mann–Whitney test. e alDH1 activity in human PC 
(N = 11); representative flow cytometry plot of human PC tumor gated 
on live epCaM+ cells using aldefluor assay. Immunofluorescent stain-
ing was performed on PC samples (N = 5) and normal human pancreas 
samples (N = 5). representative immunofluorescence confocal images 
(×63) of normal human pancreas and PC stained for epCaM, alDH1 
(green alDH1, red epCaM and blue Topro). Arrows point toward ducts 
expressing alDH1 activity. f the CD14–CD8 ratio predicts PC patient 
survival. automated analysis of CD14+ and CD8+ IHC reveals the rela-
tionship between leukocyte density and overall survival. the Kaplan–
Meier estimate of overall survival comparing CD14Hi/CD8low, CD14low/
CD8low, CD14Hi/CD8Hi, and CD68low/CD8High, is shown. Patients 
with predominant CD14+/CD8low infiltrate in the tumor had a signifi-
cantly reduced overall survival compared to all other groups (denoted as 
CD14low/CD8low, CD14Hi/CD8Hi, and CD14low/CD8Hi). there is a sta-
tistically significant difference between CD14Hi/CD8low and CD14low/
CD8Hi, p value <0.001
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Fig. 2  Myeloid cells promote CSCs and eMt in murine PC. a 
CFU-gM in bone marrow; bone marrow was isolated from tumor-
bearing and non-tumor-bearing Wt and gCSFr−/− mice (N = 7–10 
mice/group), methylcellulose-based colony-forming unit assays 
were performed and scored for total number of myeloid (CFU-
gM) colonies after 8 days. tumor-bearing Wt mice have sig-
nificantly increased myeloid colonies (CFU-gM) as compared 
to non-tumor-bearing Wt mice. gCSFr−/− mice have signifi-
cantly decreased CFU-gM as compared to non-tumor-bearing Wt 
mice (NTB non-tumor-bearing, TB tumor-bearing). b Peripheral 
blood g-MDSC (CD11b+/gr1+/ly6g+/ly6Cmid) and Mo-MDSC 
(CD11b+/gr1+/ly6g−/ly6Chi) calculated as a percentage of total 
cells. Data are shown for ntB and tB Wt and gCSFr−/− mice. c 
analysis compares tumor myeloid and lymphoid infiltrate by flow 
cytometry in Wt and gCSFr−/−, KCM tumor-bearing mice. Mo-
MDSC = CD11b+/gr1+/ly6g−/ly6Chi/F4/80mid, g-MDSC = CD11
b+/gr1+/ly6g+/ly6Cmid, t cells = CD45+/CD3+/CD4+, or CD8+, 
taM = CD45+/CD11b+/F4/80hi/ly6Clow/MHCII+. d Bar graph 
shows fold gene expression change in gCSFr−/− tumors relative to 
Wt tumors. e representative flow cytometry plot showing mouse 
orthotopic PC specimens stained for alDH1 activity. analysis by 
flow cytometry demonstrated approximately 8.2 % alDH1Bright 
CSCs in Wt tumors and 3.58 % in gCSFr−/− tumors. Bar graph 
shows fold gene expression of Slug, nanog, twist, Snail, ZeB-1, and 
OCt-4 in gCSFr−/− tumors relative to Wt tumors. f tumor growth 
curves comparing subcutaneous tumor growth, KCM by caliper 
measurements in Wt mice and gCSFr−/− mice. Points on curve rep-
resent mean values ± SeM at indicated time points. Bar graph com-
pares tumor weights of orthotopically implanted KCM in Wt and 
gCSFr−/− mice 31 days post-injection. It depicts mean ± SeM and 
asterisk denotes statistically significant difference between the two 
groups p < 0.05 by Mann–Whitney test
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total cells. We also compared the tumor infiltrate in Wt 
tumors that had different volumes (0.4 and 1.0 cm3) to rule 
out the possibility that the differences in the g-MDSC and 
Mo-MDSC infiltrate are due to different tumor sizes (Sup-
plementary figure 6 D). Furthermore, gCSFr−/− mice 
exhibit a shift in the immune profile of PC tumors from a 
tH-2 to tH-1 immune response, characterized by increased 
expression of IFn-γ, tnF-α and Il-12 with decreased 
expression of arginase-1, Il-6, tgF-β, Il-10 compared to 
Wt mice (Fig. 2d). Interestingly, tumors from gCSFr−/− 
mice had significantly reduced alDH1Bright CSCs compared 
to those from Wt mice (Fig. 2e). gCSFr−/− tumors also 
displayed decreased expression of genes associated with cell 
pluripotency (i.e. Oct-4 and nanog) and eMt (i.e. Snail, 
Slug, twist and Zeb-1 by rt-PCr) (Fig. 2e). this suggests 
that the absence of MDSC in gCSFr−/− tumors is associ-
ated with a decrease in alDH1Bright CSCs.
Ultimately, this was associated with significantly 
decreased tumor growth in both subcutaneous and ortho-
topic PC tumors in gCSFr−/− mice (Fig. 2f). these find-
ings suggest an enhanced antitumor immune response 
in gCSFr−/− mice is associated with reduced bone mar-
row-derived MDSC in the tumor. Similar results were 
found using other murine PC cell lines (Supplementary 
figure 6a–C).
Monocytic MDSC directly increase the frequency 
of alDH1Bright CSCs in murine PC
Since decreased tumor-infiltrating MDSC were associated 
with reduced alDH1Bright CSCs, we hypothesized that 
MDSC contribute to expanding the population of alD-
H1Bright CSCs. to test this, we utilized an in vitro model 
utilizing murine cell lines in order to exclude the possibil-
ity of involvement of other cell types. We cocultured in 
vitro-maintained KCM with myeloid cells from the bone 
marrow of tumor-bearing mice (cells were separated by 
transwell insert). the frequency of alDH1Bright CSCs and 
CD24+, CD44+ CSCs was significantly increased in KCM 
cocultured with CD11b+ cells, compared to KCM alone 
(Fig. 3a). However, MDSC are composed of both Mo-
MDSC and g-MDSC and perhaps only one of these two 
subsets were responsible for this observation. therefore, 
we isolated Mo-MDSC and g-MDSC from the tumors of 
Wt mice by FaCS and cocultured these cells separately 
with KCM. We found that the frequency of alDH1Bright 
CSCs was significantly increased when KCM was cocul-
tured with Mo-MDSC while there was no increase with 
g-MDSC, separated by transwell insert (Fig. 3b). this 
suggests that Mo-MDSC enhance the alDH1Bright and 
CD24+, CD44+ CSCs in PC. In order to validate this find-
ing, we also cultured murine PC tumor cells for sphere 
formation after they were cocultured with myeloids. the 
spheres were harvested and then implanted subcutaneously 
in Wt mice, and tumor growth was compared to non cocul-
tured tumor cells. the tumors grew faster when the tumor 
spheres were implanted after coculture with myeloid cells 
compared to the spheres that were not cocultured with 
myeloid cells (Fig. 3c). We also assessed changes in the 
expression of markers promoting epithelial to mesenchy-
mal transition and performed functional studies. the tumor 
cells were separated from Mo-MDSC after coculture, and 
rt-PCr and Western blotting were performed. there was 
downregulation of e-cadherin and upregulation of vimen-
tin in the tumor cells that were previously cocultured (sep-
arated by a transwell insert) with myeloid cells (Fig. 3d). 
Invasion studies further supported that tumor cells that 
were previously cocultured with myeloid cells had a mes-
enchymal phenotype and significantly invaded the Matrigel 
plug compared to the tumor cells that were not cocultured 
with myeloid cells (Fig. 3e). this suggests that Mo-MDSC 
promote CSCs in murine PC and promote mesenchymal 
properties of tumor cells.
Human pancreatic cancer converts circulating monocytes 
into Mo-MDSC
In order to study the role of Mo-MDSC in human PC, we 
cocultured normal human blood monocytes with human 
PC cell lines (Panc-1 and BxPC3). the CD14+ cells were 
harvested and assessed by flow cytometry, immune sup-
pression, rt-PCr, and Western blotting. these mono-
cytes acquired a Mo-MDSC phenotype characterized 
by a significantly decreased expression of Hla-Dr and 
increased expression of arginase-1 as well as the ability 
to suppress CD8+ t cell proliferation in vitro [29–32] 
(Fig. 4a–c). See supplementary figure 7 for similar results 
using the BxPC3 cell line. thus, tumor-derived factors in 
PC are capable of changing the phenotype and function-
ality of human blood monocytes, converting these cells 
into immunosuppressive Mo-MDSC. In PC patients with 
primary disease only, the CD14+ cells in the blood have 
a high Hla-Dr expression but these cells only obtain 
MDSC phenotypic markers when they infiltrate the tumor 
(Fig. 4d).
Mo-MDSC promote stemness in human PC by a 
Stat3-dependent mechanism
Since Mo-MDSC in mice increase the prevalence of alD-
H1Bright CSCs and enhance expression of genes associated 
with eMt in murine PC, we sought to determine if the 
same phenomenon occurs in human PC. We generated Mo-
MDSC in vitro as described above and cocultured these 
cells with PC cell lines in vitro. Both Mo-MDSC and tumor 
cells were analyzed by flow cytometry and rt-PCr after 
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Fig. 3  a KCM cultured alone and with CD11b+ cells isolated from bone 
marrow of Wt tumor-bearing mice by magnetic bead isolation, for 72 h. 
KCM tumor cells were isolated and stained for alDH1 activity and other 
CSC markers. representative flow cytometry plots show alDH1Bright 
CSCs, which constitute approximately 4.17 % when KCM is cultured 
alone and increase up to 8.09 % after coculture with CD11b+ cells. Bar 
graph shows percentage alDH1Bright and CD24+, CD44+ cancer stem 
cells in KCM, with and without coculture with CD11b+ cells. b g- and 
Mo-MDSC were isolated from orthotopically implanted KCM tumors of 
Wt mice by FaCS. these cells were separately cocultured with KCM 
for 72 h. after 72 h, KCM cells were isolated and stained for alDH1 
activity. representative flow cytometry plots show that alDH1Bright 
CSCs constitute approximately 4.39 % when KCM is cultured alone, 
5.08 % when KCM cocultured with g-MDSC and increases up to 8.5 % 
when KCM is cocultured with Mo-MDSC. c tumor growth curves com-
paring subcutaneous tumor growth, KCM spheres (with baseline alDH1 
activity) and KCM spheres after coculture (increased alDH1 activity) by 
caliper measurements in Wt mice. Points on curve represent mean val-
ues ± SeM at indicated time points. d CD11b+ cells were isolated after 
coculture with tumor cells in transwell plates and were used for Western 
blotting. Western blot analysis of KCM shows downregulation of e-cad-
herin and upregulation of vimentin in KCM from baseline after coculture 
with CD11b+ cells. e Invasion assays were performed to compare the 
invading properties of tumor cells. tumor cells were seeded in the upper 
part of Matrigel-coated transwell inserts. Cell invasion index was calcu-
lated as the number of cells attached to the bottom of Matrigel-coated 
membrane. Figure shows that KCM tumor cells have increased invasion 
through Matrigel matrix membrane after coculture relative to tumor cells 
alone. Cells per high-power field were quantified. Cells were counted in 
six different fields of triplicate membranes. Graph depicts the number of 
invaded cells per high-powered field (mean ± SeM of three independ-
ent experiments). Asterisks denotes statistically significant difference 
between the two groups p < 0.05 by Mann–Whitney test. We used 7–10 
mice per group and all these experiments were repeated in triplicate
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coculture. Consistent with our findings in mice, Mo-MDSC 
increased the alDH1Bright and CD24+, CD44+ CSC pop-
ulation in BxPC3 after coculture as compared to control 
tumor cells (Fig. 5a). In order to validate this finding, we 
also cultured human PC tumor cells for sphere formation 
after they were cocultured with CD14+ cells. the spheres 
were isolated and implanted subcutaneously in nU/J mice 
and tumor growth was compared to non-cocultured tumor 
cells. the tumors grew faster when the tumor spheres were 
implanted after coculture with Mo-MDSC, compared to 
spheres that were not cocultured with Mo-MDSC (Sup-
plementary figure 8). Consistent with enhanced tumor-ini-
tiating properties, we observed that the transcription factors 
associated with cell pluripotency and eMt, i.e., Snail, 
Slug, twist, Zeb-1, nanog, and Oct-4 were significantly 
increased by rt-PCr in PC cells cocultured with Mo-
MDSC. Invasion studies showed that the tumor cells that 
were previously cocultured with Mo-MDSC have signifi-
cantly increased invasion activity (Fig. 5b). Similar results 
were seen using Panc-1 (Supplementary figure 9). this 
suggests that human Mo-MDSC promote tumor stemness 
and eMt. additionally, we found that Il-6 expression 
was upregulated in the Mo-MDSC as compared to normal 
monocytes (Fig. 5c).
Stat3 activity in tumor cells has been demonstrated to 
facilitate the expansion and maintenance of CSCs in several 
Fig. 4  CD14+ cells were isolated from normal human PBMC by 
magnetic bead isolation and were cocultured with human PC cell 
line Panc-1 for 72 h. a Downregulation of Hla-Dr expression after 
tumor exposure; flow cytometry was performed on CD14+ cells 
(from blood) after 72 h of coculture with tumor cells. representative 
plots show that approximately 83.5 % CD14+ cells had high Hla-
Dr expression when these cells are incubated in complete medium 
(CM). after tumor exposure, these cells downregulate Hla-Dr 
expression and 71.4 % CD14+ cells have low Hla-Dr expression. b 
analysis of quantitative rt-PCr results for gene expression of argin-
ase-1 from CD14+ cells cocultured with and without tumor. normal-
ized fold change is depicted. c representative flow cytometry histo-
gram from t cell suppression assay depicts stimulated, CFSe-labeled 
CD8+ t cells cocultured with tumor-conditioned or unconditioned 
CD14+ cells for 72 h. d representative flow cytometry plot shows 
differential expression of Hla-Dr on CD14+ cells isolated from the 
blood and human tumor specimens. Bar graphs depict mean division 
index ± SeM with asterisk denotes p < 0.05 by Mann–Whitney in all 
panels
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tumor types [17]. However, we hypothesized that up regu-
lation of signal transducer and activator of transcription 3 
(pStat3) in Mo-MDSC is involved in promoting alDH-
1Bright CSCs in PC. CD14+ cells were isolated from tumor 
cells after coculture and Western blotting was performed. 
We observed that there was upregulation of phosphoryl-
ated Stat3 in tumor-treated CD14+/Hla-Drlow/− cells 
as compared to untreated CD14+ cells by Western blot-
ting (Fig. 5d). We also found upregulation of pStat3 in 
CD11b+ cells after coculture with murine PC cell lines 
(Supplementary figure 10). In order to determine if pStat3 
mediated the ability of Mo-MDSC to increase the preva-
lence of alDH1Bright CSCs, Mo-MDSC were treated with 
StattIC, a small molecule inhibitor of Stat3 [21] and 
washed with PBS. StattIC-treated cells were then plated 
in a 6-well plate, and a transwell insert was placed on 
top of the cells. Human PC tumor cells were added to the 
transwell insert and were cultured for 72 h. We found that 
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treatment with StattIC entirely prevented the Mo-MDSC 
mediated increase in alDH1Bright CSCs (Fig. 5e). In addi-
tion, we performed tumor sphere-forming assays, which 
display an increased tumor spheroid formation compared to 
control tumor cells in vitro, and treatment with StattIC 
significantly decreased the Mo-MDSC mediated increase in 
sphere formation (Fig. 5f).
Stat3 signaling in MDSC can be modulated by Il-6 
[33, 34], which has been shown to enhance CSCs and eMt 
in cancer. While we found that Il-6 mrna gene expres-
sion was significantly downregulated by Stat3 inhibition 
(Supplementary figure 11), Il-6 blockade using anti-Il-6 
antibodies decreased but did not fully reverse the effect of 
Mo-MDSC on increasing the prevalence of alDH1Bright 
CSCs. this suggests that the effects of Mo-MDSC on pro-
moting tumor stemness are likely mediated by multiple 
factors downstream of pStat3. Finally, to confirm that 
CD14+ cells express pStat3 in vivo, we performed immu-
nofluorescence staining for CD14 and pStat3 in human 
PC. Indeed, the majority of CD14+ leukocytes in the tumor 
microenvironment expressed pStat3 (Fig. 5g). these data 
suggest that pStat3 positive Mo-MDSC play an impor-
tant role in PC progression by enhancing the population of 
alDH1Bright CSCs and promoting eMt.
Discussion
PC is unique for its dense infiltrate of myeloid cells with 
a paucity of t cells. Myeloid recruitment is critical to the 
establishment and progression of PC. tumors communi-
cate with the bone marrow to increase myelopoiesis in 
both tumor-bearing mice and human PC patients. these 
myeloid cells are then recruited to the tumor microenvi-
ronment where they enhance growth and metastasis. In 
this study, we demonstrate the importance of MDSC on 
promoting the alDH1Bright CSCs in PC tumors. In our 
gCSFr−/− mouse model, we found that the reduction 
in MDSC in the tumor decreases the alDH1Bright CSC 
population. We also found that the expression of eMt 
markers and stem cell genes were downregulated in the 
tumors of gCSFr−/− mice. We further demonstrate that 
Mo-MDSC in human PC promote cancer stemness in a 
Stat3-dependent manner.
In our experiments, we found that monocytes can 
become Mo-MDSC, as they downregulate Hla-Dr 
expression and suppress t cell proliferation in the presence 
of tumor cells or tumor-derived factors (Fig. 6). this is 
important as it suggests that even mature human monocytes 
can acquire immunosuppressive properties upon exposure 
to tumor-derived factors. We have previously demonstrated 
that increased peripheral blood monocyte counts corre-
late with decreased survival in PC patients [35]. the data 
presented here suggest that the phenotype and functional 
traits of human monocytes depend on the immune environ-
ment to which these cells are exposed. therefore, target-
ing monocytes in the circulation is an attractive and novel 
Fig. 6  activation of pStat3 in the Mo-MDSC enhances the CSCs 
in the PC tumor
Fig. 5  Stat3 activity in Mo-MDSC promotes CSCs and eMt in 
PC. a CD14+/Hla-Drlow/− cells were cocultured with BxPC3 for 
72 h and alDH1, CD24, and CD44 staining was performed. graph 
shows alDH1Bright CSCs and CD24+, CD44+ cells as a percentage 
of CD45−, epCaM+, PI− cells. b tumor eMt markers and inva-
sion assay; rt-PCr shows that markers of cell pluripotency and 
eMt were upregulated in BxPC3 tumor cells after coculture with 
CD14+/Hla-Drlow/− cells. Invasion assays showing that BxPC3 
tumor cells have increased invasion through Matrigel matrix mem-
brane after coculture with CD14+ cells relative to tumor cells alone. 
Cells per high-power field were quantified. Graph depicts the num-
ber of invaded cells per high-powered field (mean ± SeM of three 
independent experiments). c analysis of quantitative rt-PCr results 
for expression of Il-6 by CD14+ cells cocultured with and without 
BxPC3 tumor. normalized fold change is depicted. d Western blot 
analysis of Stat3 phosphorylation in CD14+ cells cocultured with 
and without BxPC3 tumor cells for 72 h. e Inhibition of Stat3 
signaling in CD14+/Hla-Drlow/− cells prevents the increase in 
alDH1Bright CSCs in BxPC3 from baseline. CD14+ cells treated 
with StattIC were washed and then cocultured with tumor cells 
in transwell plates. Bar graph shows alDH1Bright CSC popula-
tion (gated on CD45−, epCaM+, PI− cells) which is approximately 
8.79 % in BxPC3 alone, 15.8 % when BxPC3 was cocultured with 
CD14+/Hla-Drlow/− cells and 6.02 % when BxPC3 was cocultured 
with StattIC-treated CD14+/Hla-Drlow/− cells. Graph shows 
that inhibition of Stat3 signaling by StattIC (20 μM) blocks the 
increase in frequency of alDH1Bright cells from baseline. f Bar graph 
shows tumor spheroid formation in BxPC3 and Panc-1 cells with and 
without CD14+/Hla-Drlow/− cells in the coculture. the mean num-
ber of tumor spheroids formatted after 10 days is depicted. g repre-
sentative immunofluorescence confocal images (×63) of human PC 
stained for CD14+ cells and pStat3 activity. Green CD14 and red 
pStat3. Bar graphs depict mean division index ± SeM with aster-
isk denotes p < 0.05 by Mann–Whitney in all panels
◂
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approach, which could decrease Mo-MDSC in the tumor 
microenvironment.
alDH1 enzyme activity defines a subpopulation of 
tumor cells which exhibit stem cell-like properties and 
whose prevalence correlates with survival in PC addition-
ally, a number of cell surface markers are co-expressed 
with alDH1, such as CD44, CD24, CD133, and CXCr4 
[36, 37]. evidence in mice suggests that alDH1 has an 
important role in the embryological development of the 
pancreas [38, 39]. However, a subpopulation of alDH-
1Bright CSCs exhibit enhanced chemoresistance and metas-
tasis [15]. Despite much progress, further work is needed to 
find better phenotypic and functional markers of CSCs in 
human malignancy.
Stat3 is a crucial transcription factor involved in 
inflammation. In murine models, pStat3 has been shown 
to regulate the expansion of myeloid progenitors as well as 
MDSC [40, 41].
Mo-MDSC depend on Stat3 for their immunosuppres-
sive properties, such as the production of arginase-1 [30]. 
We show here that Stat3 activation in Mo-MDSC is also 
critical for enhancing the CSC population in PC. It is likely 
that Stat3 phosphorylation reprograms monocytes to 
acquire a pro-tumor, immunosuppressive (MDSC) pheno-
type. We show that Stat3 inhibition completely abrogates 
the ability of Mo-MDSC to enhance the alDH1Bright CSC 
population in vitro.
Bone marrow-derived myeloid cells make up a sig-
nificant proportion of the stroma in solid tumors where 
they promote proliferation and survival of tumor cells. 
recent reports demonstrate that tumor-infiltrating mac-
rophages support early tumorigenesis by inducing eMt 
through tgF-β signaling [42]. In addition, other stud-
ies have shown that there is cross talk between MDSC 
and macrophages that polarizes macrophages into an 
M2 phenotype [43] which contribute to eMt [44]. like 
macrophages, the high frequency of Mo-MDSC-infil-
trating tumors suggests these cells are critical in mediat-
ing immune suppression in cancer patients. Our murine 
model and in vitro studies confirm that in addition to the 
direct suppression of t cells, Mo-MDSC also play an 
important role in promoting tumor stemness and eMt 
in a Stat3-dependent manner and this effect is inde-
pendent of any other cell type in the tumor. Our data 
further show that Mo-MDSC and macrophages can be 
distinguished based on expression of Hla-Dr (Figs. 4, 
5). thus, we conclude that both Mo-MDSC and mac-
rophages promote eMt, but further studies are required 
to assess possible mechanistic, spatial, and/or temporal 
differences.
Overall, our study shows that Mo-MDSC in both mice 
and humans promote alDH1Bright CSCs in PC through 
Stat3 activation. therefore, an improved understanding 
of the interactions between MDSC and CSCs is crucial for 
the development of novel therapies that may intercept this 
communication. Our findings suggest that there are mul-
tiple pathophysiologic pathways, which could be thera-
peutically targeted in PC. Blocking tumor-induced mye-
lopoiesis [45], the recruitment of monocytes to the tumor 
microenvironment, e.g., through blockade of chemokine 
receptors, the conversion of monocytes into Mo-MDSC, 
and the Stat3-dependent enhancement of tumor stemness 
all offer opportunities to thwart the tumor-promoting 
effects on myeloid cells in this disease. In conclusion, we 
show that monocytes can become Mo-MDSC in the pres-
ence of tumor by acquiring immunosuppressive properties. 
Furthermore, Mo-MDSC infiltrate tumors where they pro-
mote cancer stemness in a Stat3-dependent manner.
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